Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.
Research context
Vyne Therapeutics Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
VYNE Therapeutics Inc is currently in a long term downtrend where the price is trading 50.7% below its 200 day moving average.
From a valuation standpoint, the stock is 99.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 10.7.
VYNE Therapeutics Inc's total revenue rose by inf% to $4M since the same quarter in the previous year.
Its net income has increased by 68.5% to $-23M since the same quarter in the previous year.
Finally, its free cash flow fell by 54.6% to $-25M since the same quarter in the previous year.
Based on the above factors, VYNE Therapeutics Inc gets an overall score of 3/5.